In this Issue:
Recent consensus on treating MM with high-risk cytogenetics
Salvage ASCT – effect on OS in patients with relapsed MM
Upfront ASCT – the effect on survival in elderly patients
MRD monitoring and immune profiling in elderly MM patients
Monoclonal antibody therapy – depletion of CD38+ and subsequent benefits of daratumumab
Marizomib in RRMM – results of a phase 1 study
Promising results from a phase I/II study using bendamustine, low-dose dexamethasone and lenalidomide in combination therapy
Melflufen, a novel alkylating agent, kills melphalanresistant tumour cells
Renal impairment – a phase III study of pomalidomide based therapy
Please login below to download this issue (PDF)